All posts by: Michael Zand

About Michael Zand

Genes physically held in silencing ‘lock-down’ in embryonic stem cells – Medical Xpress

Continue reading

2015-08-31 NEWS

Medical Xpress

Genes physically held in silencing ‘lock-down’ in embryonic stem cells
Medical Xpress
The research, reported online in Nature Genetics, presents how key decision-making genes which specify the embryo’s blueprint for subsequent development are physically clustered in the nucleus of embryonic stem cells and maintained in a silent state.

Continue reading

2015-08-31 NEWS

Asterias’s stem cell therapy shows promise in study
Yahoo News
(Reuters) – Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury. The company’s shares were up 25 percent at $5.26 in mid-day

and more »

Continue reading

2015-08-31 NEWS

Asterias’s stem cell therapy shows promise in study
Reuters
Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury. The therapy, AST OPC-1, is the first product derived from human embryos to be

and more »

Continue reading

2015-08-31 NEWS

Reuters

Asterias’s stem cell therapy shows promise in study
Reuters
Asterias Biotherapeutics Inc said initial data from a small study showed that its lead stem cell therapy could improve mobility in patients paralyzed by a spinal cord injury. The company’s shares were up 25 percent at $5.26 in mid-day trading on heavy

and more »

Continue reading

2015-08-31 NEWS

Successful BNC101 IND Submission Paves Way for Development of Promising Cancer
PR Newswire (press release)
“BNC101 is a new class of anti-cancer agent which targets cancer stem cells. Many current drugs do not specifically target cancer stem cells. We believe that specific drugs, such as BNC101, targeting cancer stem cells will reduce the risk of cancer

and more »